Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.24.3
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
REVENUE $ 33 $ 23 $ 55 $ 479
OPERATING EXPENSES:        
Research and development expenses 878 392 1,517 712
Selling and marketing expenses 431 95 973 399
General and administration expenses 2,992 183 4,183 879
TOTAL OPERATING EXPENSES 4,301 670 6,673 1,990
OPERATING LOSS (4,268) (647) (6,618) (1,511)
OTHER INCOME (EXPENSE)        
Interest and bank fees (24) (3) (36) (13)
Unrealized gain (loss) on foreign exchange (2) 0 1 0
Other (expense), net 5 0 (22) (2)
LOSS BEFORE INCOME TAX (4,289) (650) (6,675) (1,526)
Income tax provision 0 0 0 0
NET LOSS AND COMPREHENSIVE LOSS $ (4,289) $ (650) $ (6,675) $ (1,526)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (0.61) $ (0.18) $ (1.15) $ (0.49)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING, BASIC AND DILUTED (in shares) 7,080,897 3,678,906 5,828,054 3,083,214